

CURRICULUM VITAE

Prepared 5/15/19

Name: Michael Henry Rosenbloom

Position: HealthPartners Neurology Department Chair
Clinical Director, HealthPartners Center for Memory and Aging;

Office Address:
HealthPartners Neuroscience Center
Department of Neurology
295 Phalen Boulevard
St. Paul, MN 55130

Place of Birth: Abington, PA

EDUCATION

8/1996-5/00:	Johns Hopkins University	B.A.	Magna cum Laude, Neuroscience and Writing
8/2000-5/04:	Columbia University	M.D.	
7/2004-6/05:	Bassett Hospital	Intern	Medicine
7/2005-6/08:	Partners Healthcare	Resident	Neurology
	Mass General Hospital		
	Brigham and Women's Hospital		
7/08-6/09:	University of California, San Francisco	Clinical Fellow/Clinical instructor	
	Memory and Aging Center		
7/09-6/10:	GRECC Research Fellowship Bedford VA Medical Center	Research fellow	

CONTINUING EDUCATION

3/15-10/15 National Institute of Neurological Diseases and Stroke (NINDS) Clinical Trial Methodology Course
6/15-4/16 Leadership Training (48 hours from the Collabrium Leadership Coaching)

MEDICAL EMPLOYMENT:

7/10- HealthPartners Center for Memory and Aging
9/14-8/16 University of Minnesota, Department of Neurology (Assistant residency director/assistant professor)

LICENSES, CERTIFICATION:

4/08 California Medical License
1/09: American Board of Psychiatry and Neurology Certification
8/09: Massachusetts Medical License
9/10-: Minnesota Medical License

PROFESSIONAL ORGANIZATIONS:

Memberships

8/00-6/04: American Medical Association
7/05-: American Academy of Neurology
1/11-: Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment
11/12-: Minnesota Society of Neurological Sciences

KEYWORDS/AREAS OF INTEREST:

Frontotemporal dementia, Lewy body dementia, Atypical presentations of Alzheimer's Disease, Comportment, Rapidly progressive dementia, intranasal insulin

TEACHING AND MENTORING:

Undergraduate 9/96-5/00

Johns Hopkins University
Tutor, Organic Chemistry/Calculus II
Johns Hopkins Tutorial Project
Jail Tutorial Project
Creative Writing Course at Rowland Park Elementary School in Baltimore, MD
Tutor, Johns Hopkins Writing Center

Medical School 8/00-5/04

Student Success Network: Histology Tutor
S-PREP (State Pre-College Enrichment Program)

Practice-Based 9/11-

HealthPartners Neurology Site Director for University of Minnesota Resident/Medical Student Education
Co-Founder, Partners in Dementia Buddy Program

TEACHING AWARDS AND NOMINATIONS:

4/2002: SPREP Teaching Award for tutoring minority high school students in preparation for medical careers

RESEARCH AND CREATIVE ACTIVITIES

University 8/96-5/00

Advertising Editor, *Johns Hopkins News-Letter*
Tutor, Johns Hopkins Writing Center
Johns Hopkins Emergency Response Unit
Member, Johns Hopkins Film Club

Medical School 8/00-5/04

Writer/photographer, *Reflexions Literary Magazine*
SSN, Walker Percy Society
Legal Aid Society (medical consultation for non-profit lawyers)

HONORS AND AWARDS:

8/96-5/00: Johns Hopkins University, Neuroscience with Honors, Magna cum Laude, Writing Seminars Project Award, Phi Beta Kappa Society

8/00-5/04: Columbia University: S-PREP Teaching Award
 11/12-: President Minnesota Society of Neurological Sciences
 9/14: Minnesota Business Magazine Leaders in Healthcare Award Finalist: Change Agent
 5/15: Vice-Chair, Alzheimer's Association Medical and Scientific Advisory Committee (MSAC)-MN-SD
 7/15: R-25 Award-National Institute of Neurological Diseases and Stroke (NINDS) Clinical Trial Methodology Course (CTMC)
 10/15 HealthPartners 2015 President's Award Nominee
 10/15- Minnesota Monthly Best Doctors (Alzheimer's disease) 2015-2016
 12/16 Fellow, American Academy of Neurology
 11/17 Modern Healthcare Magazine-2017 Up and Comers
 11/17 HealthPartners Center for Memory and Aging Leadership Award
 1/18 Chair, Alzheimer's Association Medical and Scientific Advisory Committee (MSAC)-MN-SD
 4/18- Minneapolis-St. Paul Magazine Top Doctors-Rising Stars

BOARDS AND COMMITTEES:

11/10- 6/15: Regions Hospital Medical Executive Committee (MEC)
 11/10-6/15: Clinical Care Committee (CCC)
 01/11-2/13: HealthPartners Research Foundation Clinical Research Subcommittee (CRS)
 11/11- : Act on Alzheimer's (Leadership Council)
 11/11- : Alzheimer's Association Medical and Scientific Advisory Committee (MSAC)
 2/16- : MICT-PD, Chair of Data Safety and Monitoring Board (DSMB)
 4/16- : American Board of Psychiatry and Neurology (ABPN) Maintenance of Certification (MOC) Clinical Advisory Committee
 1/18-10/18: Minnesota Department of Aging-Alzheimer's Working Group Member

CLINICAL RESEARCH:

Principal Investigator.

Center for Memory and Aging, Neuroscience Center, St. Paul, Minnesota.

A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glutamine on Cognitive Function and Memory in Individuals Diagnosed with Probable Mild to Moderate Alzheimer's Disease.

A Phase 3 Randomized, Double-Blind Placebo Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human) 10% Solution (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

The 6th Vital Sign Project: Does Cognitive Screening in the Elderly Population Improve Clinical Care?

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease.

A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)

A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease.

A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome.

Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; study 2.

A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnesic Mild Cognitive Impairment and Probable Mild Alzheimer's disease.

Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study:

BN29553: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease.

GN39763: A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients with Prodromal to Mild Alzheimer's Disease.

CAP1015A2201J: A Randomized, Double-blind, Placebo-Controlled, Two Cohort Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.

Grants and Awards:

The 6th Vital Sign Project: Does Cognitive Screening in the Elderly Population Improve Clinical Care? (internal grant from HealthPartners Institute for Education and Research/University of Minnesota)

R-25 Award-National Institute of Neurological Diseases and Stroke (NINDS) Clinical Trial Methodology Course (CTMC)

Regions Hospital Internal Red Grant for Amyloid Pet imaging in a community neurology practice: feasibility and clinical outcomes

Merck Foundation Grant for HealthPartners Care Ecosystem

PUBLICATIONS

Original Publications and Clinical Communications

1. **Rosenbloom MH.** Singhal A. CT Angiography and Diffusion-Perfusion MR Imaging in a Patient with Ipsilateral Reversible Cerebral Vasoconstriction after Carotid Endarterectomy. *Am J Neuroradiol.* 2007; 28(5):920-2.
2. **Rosenbloom MH.** Finley R. Scheinman MM. Miller B. Rabinovici G. Donepezil Associated Bradarrhythmia in a Patient with DLB. *Alzheimer's Disease and Associated Disorders.* 2010;24(2):209-11.
3. **Rosenbloom, MH.** Brown J. Berlowitz D. Budson A. Safety and Tolerability of galantamine SA in Dementia Patients Transitioned from Donepezil. *The Consulting Pharmacist.* 2011 Feb; 26(2): 108-10.
4. **Rosenbloom MH.** Alkalay A. Agerwal N. Baker SL. O'Neill JP. Janabi M. Yen IV. Growdon M. Jung J. Madison C. Rosen HJ. Gorno-Tempini ML. Weiner MW. Miller BL. Jagust WJ. Rabinovici GD. Distinct Clinical and Metabolic deficits in Alzheimer's Disease and Posterior Cortical Atrophy are Not Related to Amyloid Distribution. *Neurology.* 2011. 24;76(21):1789-96.
5. **Rosenbloom MH,** Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. *CNS Drugs.* 2014 Dec;28(12):1185-9.
6. **Rosenbloom MH.** Borson S. Barclay T. Hanson LR. Werner A. Stuck L. McCarten J. Routine cognitive screening in a neurology practice. *Neurol Clin Pract.* October 29, 2015.
7. **Rosenbloom MH,** Tartaglia MC, Forner SA, Wong K, Kuo A, Johnson D, Colacurcio V, Andrews B, Bruce Miller B, DeArmond S, and Geschwind M. Metabolic disorders with clinical and radiological features of sporadic Jakob-Creutzfeldt Disease. *Neurol Clin Pract.* 2015 Apr;5(2):108-115.
8. **Rosenbloom, MH.** Ziegler R. Barclay M. Woll A. Smith J. Training Residents in a Best Practice Approach to the Diagnosis and Management of Alzheimer's Disease. MedEdPORTAL Publications.
9. *Gertner, E. **Rosenbloom, MH.** Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report. *J Med Case Rep.* 2016 May 27; 10(1);137.
10. **Rosenbloom, MH.** Samuelsson, M. Brogan, M. Tran-Lim, T. NMDA-Receptor Antibody Encephalitis Presenting with Enhancing Lesion and Seizures. *Neurology Clin Pract.* Accepted for publication.
11. **Rosenbloom, M.** Barclay TR. Borson S. Werner AM. Erickson LO. Crow JM. Lakshminarayan K. Stuck LH. Hanson LR. Screening Positive for Cognitive Impairment: Impact on Healthcare Utilization and Provider Action in Primary and Specialty Care Practices. *J Gen Intern Med.* 2018 Oct; 33(10):1746-1751.

12. Amanda, AA. Othman, SI. DeFoe KM. Carolan EJ. **Rosenbloom MH.** Spinal epidural abscess: Esophageal fistula as a potential infection source. *Interdisciplinary Neurosurgery* 2019; 16: 42-43.

Reviews, Chapters, and Editorials

1. **Rosenbloom M.** Chlorpromazine and the psychopharmacologic revolution. *JAMA*. 2002. 10;287(14):1860-1
2. **Rosenbloom MH.** Chao S. Thai J. Geschwind MD. Evaluation of Memory Loss. *BMJ In Practice* (www.epocrates.com).
3. **Rosenbloom MH.** Smith S. Yener G. Geschwind MD. The Immune-Mediated Dementias. *Current Neurology and Neuroscience Reports* 2009; 9(5): 359-67.
4. **Rosenbloom MH.** Atri A. The Evaluation of Rapidly Progressive Dementia. *The Neurologist*. 2011; 17(2):67-74.
5. Barclay T. Barclay M. **Rosenbloom M.** Living Well: A Guide for Persons with Mild Cognitive Impairment and Early Dementia. Alzheimer's Association. 2011.
6. **Rosenbloom MH.** Schmahmann JD. Price BH. The Functional Neuroanatomy of Decision-Making. *Journal of Neuropsychiatry and Clinical Neurosciences*. J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):266-77.
7. Editor, Act on Alzheimer's Dementia Curriculum Modules 2012.
8. **Rosenbloom MH.** Price B. Freudenreich O (2013). Comportment: Structure and Function in *Neurology and Neuropsychiatry* (pgs 250-265). Cambridge, UK: Cambridge University Press.
9. Roohani P. Saha MK. **Rosenbloom MH.** Creutzfeldt-Jakob Disease in the Hospital Setting. *Minnesota Medicine*. May 2013: 46-49.
10. Kerchner GA. **Rosenbloom MH** (2014). Frontotemporal Neurocognitive Disorder. Gabbard's Treatment of Psychiatric Disorders. (pgs 967-976). Washington DC: American Psychiatric Publishing.
11. **Rosenbloom MH.** Kerchner GA. Frontotemporal Dementia. Textbook of Neuropsychiatry and Behavioral Neurosciences. 6th ed. American Psychiatric Publishing (submitted for publication).
12. Starks, J. **Rosenbloom, MH.** Management of Psychiatric Features in Frontotemporal Dementia. *Psychiatric Annals*. May 2017.

Abstracts

1. **Rosenbloom MH.** Lee S. Glenn S. Chan A. Racine CA. Miller BL. First Symptoms in Pathologically-Confirmed Corticobasal Degeneration, Progressive Supranuclear Palsy and Frontotemporal Dementia with Motor Neuron Disease (American Academy of Neurology Conference 2009).
2. **Rosenbloom MH.** Rabinovici GD. Alkalay A. Baker SL. O'Neill JP. Yen IV. Growdon J. Jung J. Madison C. Miller BL. Jagust WJ. AB Amyloid and Glucose Metabolism in Posterior Cortical Atrophy (Human Amyloid Imaging Conference 2009).
3. **Rosenbloom MH.** Alkalay A. Agerwal N. Baker SL. O'Neill JP. Janabi M. Yen IV. Growdon M. Jung J. Madison C. Miller BL. Jagust WJ. Rabinovici GD. Distinct Clinical and Metabolic deficits in Alzheimer's Disease and Posterior Cortical Atrophy are Not Related to Amyloid Distribution. (American Academy of Neurology Conference 2010).
4. **Rosenbloom, M.** Barclay, T. R., Perfect, D., Pyle, M., Kiihn, M., Zahs, K., Lakshminarayan, K., Cleary, J. P. Ashe, K. & Hanson, L. The 6th Vital Sign Project: Does cognitive screening in the elderly population improve clinical care? (Alzheimer's Association International Conference 2012)
5. Hurliman E, Koffel J, **Rosenbloom M** & Tiriyaki E. Neurology Survival Guide: Ebook and App Development (American Academy of Neurology Conference 2013).
6. **Rosenbloom MH.** Barclay TR. Pyle M. Cagan A. Anderson CP. Frey II WH. Hanson LH. The Effect of Rapidly Acting Intranasal Insulin on ApoE4 Carriers with Mild-Moderate Alzheimer's Disease. (Alzheimer's Association International Conference 2013).
7. **Rosenbloom MH MD,** Lakshminarayan K, Barclay TR , Pyle M, Cagan A, Stuck L, Hanson LH. The 6th Vital Sign Project: Is Cognitive Screening in the Elderly Population Clinically Effective? (University of Minnesota Clinical and Translational Science Institute Conference 2013).
8. **MH Rosenbloom MD,** TR Barclay PhD, M Pyle RN, AB Cagan BA, AM Hanson MS, LH Stuck MS, LR Hanson PhD. Cognitive Screening in a General Neurology Clinic: Impact on Physician Behavior (American Academy of Neurology Conference 2014).
9. Leah R. Hanson, Terry R. Barclay, Ann M. Hanson, Logan H. Stuck, Maria X. Pyle, Amanda B. Cagan, **Michael Rosenbloom.** Failure on Cognitive Screening Predicts Increased Healthcare Utilization (HMO Research Network Meeting 2014)
10. Leah R. Hanson, Terry R. Barclay, Ann M. Hanson, Logan H. Stuck, Jean M. Crow, **Michael H Rosenbloom.** Identification of Multiple Chronic Conditions that Yield the Highest Impact of Cognitive Screening (HMO Research Network Meeting 2015).
11. **Michael H Rosenbloom,** Terry Barclay, Jean Crow, Ann Hanson, Logan Stuck, Soo Borson, and Leah R Hanson. Routine Cognitive Screening in a Neurology Practice: Impact on Physician Behavior (Alzheimer's Association International Conference 2015).

12. Leah R. Hanson, Terry R. Barclay, Ann M. Werner, Lauren O. Erickson, Jean M. Crow, Soo Borson, Kamakshi Lakshminarayan, **Michael Rosenbloom**. Outcomes from Routine Cognitive Screening in a Health Care System (Alzheimer's Association International Conference 2015).
13. Hanson, LR. Barclay, TR. Werner, AM. Erickson, LO. Crow, JM. Borson, S. Lakshminarayan, K. **Rosenbloom, MH**. Outcomes from Routine Cognitive Screening in a Health Care System (Alzheimer's Association International Conference 2016).
14. **Rosenbloom, MH**. Starks, J. Roy, M. Medical Student Observations and Reflections from a Memory Disorders Buddy Program: A Qualitative Analysis (accepted as oral session for Alzheimer's Association International Conference 2017)
15. **Rosenbloom, MH**. Barclay, TR. Werner AM. Erickson, LO. Kashyap, B. Dorwat, A. Borson, S. Hanson, LR. Results of Cognitive Screening from the Primary Care Medicare Annual Wellness Visit (accepted as poster session for Alzheimer's Association International Conference 2017).
16. **Rosenbloom MH**. Wyman-Chick KA. Erickson LO. Carolan P. Johnson J. Pyle M. Barclay TR. Amyloid PET Imaging in a Community Neurology Practice: Feasibility and Clinical Outcomes (accepted as a poster session for Alzheimer's Association International Conference 2018).
17. **Rosenbloom MH**. Pyle M. Erickson L. Schlichting J. Barclay T. Hanson L. Intranasal Glutamine in Down Syndrome: A Pilot Safety and Tolerability Trial (accepted as a poster for the American Academy of Neurology 2019).
18. Wyman-Chick KA. Weintraub D. Erickson LO. **Rosenbloom MH**. Martin PK. Barclay TR. Barrett MJ. Neuropsychiatric and motor symptoms in prodromal dementia with Lewy bodies (accepted as a poster at International DLB Conference 2019).